AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82

Early Phase 1

Completed

Conditions: Sarcoidosis

Interventions: Drug: Fluorodeoxyglucose
Drug: Rubidium
Diagnostic Test: FDG-PET/CT with Rb82 Myocardial Perfusion Imaging

First Posted Date: 2017-02-09

Last Posted Date: 2019-08-26

Lead Sponsor: Yale University

Target Recruit Count: 15

Registration Number: NCT03048097

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy

Phase 2

Completed

Conditions: Binge-Eating Disorder
Obesity

Interventions: Drug: NB medication (Naltrexone Bupropion combination)
Other: Placebo

First Posted Date: 2017-02-08

Last Posted Date: 2024-02-02

Lead Sponsor: Yale University

Target Recruit Count: 68

Registration Number: NCT03047005

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

Community Partnership for Healthy Sleep

Completed

Conditions: Pediatric Sleep

First Posted Date: 2017-02-08

Last Posted Date: 2019-07-05

Lead Sponsor: Yale University

Target Recruit Count: 83

Registration Number: NCT03045874

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

Phase 2

Completed

Conditions: Binge-eating Disorder
Obesity

Interventions: Drug: NB medication (Naltrexone Bupropion combination)
Behavioral: Behavioral Weight Loss (BWL) counseling
Other: Placebo

First Posted Date: 2017-02-07

Last Posted Date: 2023-03-08

Lead Sponsor: Yale University

Target Recruit Count: 136

Registration Number: NCT03045341

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

Pivotal Response Treatment (PRT) Telemedicine

Not Applicable

Completed

Conditions: Autism Spectrum Disorder

Interventions: Behavioral: Pivotal Response Treatment

First Posted Date: 2017-02-07

Last Posted Date: 2020-06-26

Lead Sponsor: Yale University

Target Recruit Count: 7

Registration Number: NCT03045263

Locations: 🇺🇸
Yale Child Study Center, New Haven, Connecticut, United States

Aggressive Incidents in Medical Settings Study

Completed

Conditions: Aggression

First Posted Date: 2017-02-02

Last Posted Date: 2020-03-06

Lead Sponsor: Yale University

Target Recruit Count: 137

Registration Number: NCT03041272

Locations: 🇺🇸
Yale New Haven Hospital Primary Care Center, New Haven, Connecticut, United States
🇺🇸
Middlesex Hospital, Middletown, Connecticut, United States
🇺🇸
Yale New Haven Hospital- St. Raphael, New Haven, Connecticut, United States

A New Wizard for Insulin Sensitivity Estimation From SAP: a Randomized Controlled Trial in Adolescents With T1D

Not Applicable

Withdrawn

Conditions: Diabetes Mellitus

Interventions: Other: individualized insulin sensitivity index (ISind)

First Posted Date: 2017-01-27

Last Posted Date: 2019-07-11

Lead Sponsor: Yale University

Registration Number: NCT03034759

Locations: 🇺🇸
Yale Pediatric Diabetes Research Program, New Haven, Connecticut, United States

Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression

Not Applicable

Completed

Conditions: Depressive Disorder, Major

Interventions: Other: Cognitive behavioral therapy (CBT) and medication
Other: Psychoeducation and medication

First Posted Date: 2017-01-23

Last Posted Date: 2020-02-05

Lead Sponsor: Yale University

Target Recruit Count: 28

Registration Number: NCT03027362

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

Phase 1

Completed

Conditions: Type II; Diabetes
Heart Failure

Interventions: Drug: Empagliflozin
Drug: Placebo Oral Capsule

First Posted Date: 2017-01-23

Last Posted Date: 2020-06-26

Lead Sponsor: Yale University

Target Recruit Count: 21

Registration Number: NCT03027960

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: anetumab ravtansine

First Posted Date: 2017-01-18

Last Posted Date: 2021-10-28

Lead Sponsor: Yale University

Target Recruit Count: 18

Registration Number: NCT03023722

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Home Terms & Conditions Privacy Policy